

CUTTING, Simon M.  
Appl. No. 10/506,749  
January 22, 2008

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

32. (Currently amended) A Bacillus spore which comprises a promoter and at least one genetic construct that is under the control of the promoter and that encodes a ~~therapeutically active compound~~ heterologous antigen and:

- (i) linked to a signal sequence for said protein;
- (ii) as part of a chimeric gene with a vegetative cell protein of said Bacillus; or
- (iii) as part of a chimeric gene with the rRNA of the *rrnO* gene;

wherein the spore is suitable for use in oral administration for therapeutic treatment.

33.-35. (Cancelled).

36. (Currently amended) A spore as claimed in claim 32, wherein the ~~spore has been produced~~ genetic modification is accomplished by transformation of a mother cell using ~~said~~ genetic construct a vector containing the gene construct and then inducing the mother cell to produce the spores.

37. (Currently amended) A spore as claimed in claim 32, wherein the ~~gene~~ genetic construct is under the control of one or more of, each or independently, an inducible promoter or a strong promoter or modified promoter.

CUTTING, Simon M.  
Appl. No. 10/506,749  
January 22, 2008

38. (Cancelled).

39. (Currently amended) A spore as claimed in claim 37, wherein the gene-genetic construct has an enhancer element or an upstream activator sequence associated with it.

40. (Previously presented) A spore as claimed in claim 32, wherein the construct comprises an inducible expression system.

41. (Previously presented) A spore as claimed in claim 37, wherein the construct comprises an inducible expression system.

42. (Previously presented) A spore as claimed in claim 32, wherein the spore germinates in the duodenum and/or the jejunum of an intestinal tract of a human or animal body.

43. (Currently amended) A spore as claimed in claim 32, wherein the antigen therapeutically active compound is an antigen which, in use, is adapted to elicit an immune response.

44. (Currently amended) A spore as claimed in claim 43, wherein the antigen is at least a fragment of tetanus toxin fragment C or labile toxin B sub-unit.

CUTTING, Simon M.  
Appl. No. 10/506,749  
January 22, 2008

45.-46. (Cancelled).

47. (Currently amended) A spore as claimed in claim 37, wherein the vegetative cell protein is expressed all the time in a vegetative cell.

48. (Cancelled).

49. (Currently amended) A spore as claimed in claim 47, wherein the vegetative cell protein is OppA.

50. (Currently amended) A spore as claimed in claim 32, wherein the vegetative cell protein is expressed intermittently in a vegetative cell.

51. (Cancelled).

52. (Currently amended) A spore as claimed in claim 32, wherein the vegetative cell protein is a soluble cytoplasmic vegetative cell protein.

53. (Currently amended) A spore as claimed in claim 44, wherein the vegetative cell protein is soluble cytoplasmic vegetative cell protein.

54. (Previously presented) A spore as claimed in claim 32, wherein the spore encodes the rRNA of the *rrnO* gene.

CUTTING, Simon M.  
Appl. No. 10/506,749  
January 22, 2008

55.-56. (Cancelled).

57. (Currently amended) A spore as claimed in claim 32, wherein the signal sequence is adapted to target the antigen therapeutically active compound to a specific part of the vegetative cell.

58. (Currently amended) A spore as claimed in claim 44, wherein the signal sequence is adapted to target the antigen therapeutically active compound to a specific part of the vegetative cell.

59. (Currently amended) A spore as claimed in claim 57, wherein the signal sequence directs the heterologous antigen therapeutically active compound for secretion (~~preferably active secretion, more preferably Type I, Type II or Type III secretion~~), or for post-translational processing by a vegetative cell (~~preferably glycosylation~~).

60.-66. (Cancelled).

67. (Currently amended) A composition comprising at least two different spores as defined in claim 32, wherein said at least two different spores express at least two different heterologous antigens therapeutically active compounds.

CUTTING, Simon M.  
Appl. No. 10/506,749  
January 22, 2008

68. (Previously presented) A composition as defined in claim 67, wherein the composition further comprises a pharmaceutically acceptable excipient or carrier.

69. (Previously presented) A composition comprising a spore as defined in claim 32 in association with a pharmaceutically acceptable excipient or carrier.

70.-74. (Cancelled).

75. (Withdrawn and Currently amended) A method of medical treatment for vaccinating a human or animal, which method comprises the steps of a) orally administering a Bacillus spore as defined in claim 32 to human or animal in need of medical treatment; where the administered Bacillus comprises a promoter and at least one genetic construct that is under the control of the promoter and that encodes a heterologous antigen and

(i) a signal sequence for said heterologous antigen,

(ii) is part of a chimeric gene with a vegetative cell protein of said Bacillus, or

(iii) as part of a chimeric gene with the rrnO gene,

wherein the spore is suitable for use in oral administration for therapeutic treatment

b) —— said spore germinating into a vegetative cell in the intestinal tract;

c) —— said vegetative cell expressing a therapeutically active compound for use in the medical treatment.

76.-79. (Cancelled).

CUTTING, Simon M.  
Appl. No. 10/506,749  
January 22, 2008

80. (New) A spore as claimed in claim 59, wherein the signal sequence directs the therapeutically active compound for active secretion or for post-translational processing by glycosylation.

81. (New) A spore as claim in claim 80 wherein the active secretion is Type I, Type II or Type III secretion.